Suppression of Tumor Immune Activity in Adrenocortical Carcinoma with Excess Glucocorticoid
Greenstein et al. • 2020 • AACR Annual Meeting 2020
© 2024 Corcept Therapeutics, Incorporated
Impact of relacorilant, a selective glucocorticoid receptor antagonist, on the immunosuppressive effects of endogenous cortisol.
Greenstein et al. • 2020 • Citation: J Clin Oncol 38: 2020 (suppl; abstract #: 3091)
Relacorilant With Nab-paclitaxel: Safety and Activity in Patients With Pancreatic Ductal Adenocarcinoma and Ovarian Cancer
Munster et al. • 2019 •
Selective Glucocorticoid Receptor Modulators (SGRMs) delay castrate-resistant prostate cancer growth.
Kach et al. • 2017 • Mol Cancer Ther. 2017;16(8):1680-1692.
Glucocorticoid receptor expression in 20 solid tumor types using immunohistochemistry assay.
Block et al. • 2017 • Cancer Manag Res. 2017;9:65-72.
Steroid receptors aplenty in prostate cancer.
Sharifi N. • 2014 • N Engl J Med. 2014;370(10):970-1.
“Targeting” triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers.
Nanda R. • 2011 • Semin Oncol. 2011;38(2):254-62.
Minireview: nuclear receptors and breast cancer.
Conzen SD • 2008 • Mol Endocrinol.2008;22(10):2215-28.
The biology of hormone refractory prostate cancer. Why does it develop?
Isaacs JT • 1999 • Urol Clin North Am. 1999;26(2):263-73.
Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma.
Stringer-Reasor et al. • 2015 • Gynecol Oncol. 2015;138(3):656-62.